Skip to main content
Top
Published in: BMC Cancer 1/2011

Open Access 01-12-2011 | Research article

Serum levels of MMP-11 correlate with clinical outcome in Chinese patients with advanced gastric adenocarcinoma

Authors: Dong Yan, Hong Dai, Jin-Wei Liu

Published in: BMC Cancer | Issue 1/2011

Login to get access

Abstract

Background

The aim of the present study was to investigate the association between serum levels of matrix metalloproteinase 11 (MMP-11) and responses to front-line chemotherapy and prognosis in advanced unresectable gastric adenocarcinoma.

Methods

Clinical data concerning 86 patients with advanced gastric adenocarcinoma (stages III c to IV), treated in Beijing Chao-Yang Hospital from 2005 to 2009, were reviewed retrospectively. Adenocarcinoma was confirmed by pathology and patients received 5-fluorouracil-based front-line combination chemotherapy with third generation chemotherapeutic agents including paclitaxel, docetaxel and oxaliplatin. The regimen was repeated every two to three weeks, and the first evaluation was carried out after three cycles. The median cycle of chemotherapy was 6 (ranging from three to twelve cycles). Serum MMP-11 protein from the 86 patients was examined using enzyme-linked-immunosorbent-assay (ELISA) prior to chemotherapy and after three cycles of chemotherapy. Serum samples from healthy individuals were used as controls.

Results

The response rate (RR, complete response plus partial response) to chemotherapy in the 86 patients was 44.2% (38/86). The median TTP (time to progression) and overall survival (OS) in patients who responded to chemotherapy were 6.0 and 10.0 months, respectively. The response rate to chemotherapy in patients with high levels of serum MMP-11 (42.9%; 9/21) was similar to that in patients with low levels (44.6%; 29/65) (P = 0.935). Patients with low serum levels of MMP-11 had a higher median survival time and 1-year survival rate than those with high levels (11 months vs. 8 months, 50.2% vs. 21.7%, P = 0.017), although the TTP was comparable in all patients, irrespective of serum MMP-11 level (P = 0.178). Serum MMP-11 levels were correlated with lymph node metastasis (P = 0.006). Cox multivariate regression analysis demonstrated that the serum level of MMP-11 was an independent prognostic factor for patients presenting with advanced gastric carcinoma.

Conclusions

Serum levels of MMP-11 in Chinese patients with advanced gastric carcinoma were not associated with the response to front-line chemotherapy, but could play an important role in lymph node metastasis and prognosis.
Appendix
Available only for authorised users
Literature
1.
go back to reference Lustosa SA, Saconato H, Atallah AN, Lopes Filho Gde J, Matos D: Impact of extended lymphadenectomy on morbidity, mortality, recurrence and 5-year survival after gastrectomy for cancer: Meta-analysis of randomized clinical trials. Acta Cir Bras. 2008, 23: 520-530. 10.1590/S0102-86502008000600009.CrossRefPubMed Lustosa SA, Saconato H, Atallah AN, Lopes Filho Gde J, Matos D: Impact of extended lymphadenectomy on morbidity, mortality, recurrence and 5-year survival after gastrectomy for cancer: Meta-analysis of randomized clinical trials. Acta Cir Bras. 2008, 23: 520-530. 10.1590/S0102-86502008000600009.CrossRefPubMed
2.
go back to reference Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM: Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol. 2000, 18: 1135-1149.PubMed Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM: Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol. 2000, 18: 1135-1149.PubMed
3.
go back to reference Drác P, Klein J, Tichý T, Kolek V, Skarda J: Prognostic impact of matrix metalloproteinases 2, 9 and 11 in stromal cells stage I non-small cell lung cancer. Cas Lek Cesk. 2007, 146: 45-47. [In Czech]PubMed Drác P, Klein J, Tichý T, Kolek V, Skarda J: Prognostic impact of matrix metalloproteinases 2, 9 and 11 in stromal cells stage I non-small cell lung cancer. Cas Lek Cesk. 2007, 146: 45-47. [In Czech]PubMed
4.
go back to reference Vazquez-Ortiz G, Pina-Sanchez P, Vazquez K, Duenas A, Taja L, Mendoza P, Garcia JA, Salcedo M: Overexpression of cathepsin F, matrix metalloproteinases 11 and 12 in cervical cancer. BMC cancer. 2005, 5: 68-10.1186/1471-2407-5-68.CrossRefPubMedPubMedCentral Vazquez-Ortiz G, Pina-Sanchez P, Vazquez K, Duenas A, Taja L, Mendoza P, Garcia JA, Salcedo M: Overexpression of cathepsin F, matrix metalloproteinases 11 and 12 in cervical cancer. BMC cancer. 2005, 5: 68-10.1186/1471-2407-5-68.CrossRefPubMedPubMedCentral
5.
go back to reference Bartolomé RA, Ferreiro S, Miquilena-Colina ME, Martínez-Prats L, Soto-Montenegro ML, García-Bernal D, Vaquero JJ, Agami R, Delgado R, Desco M, Sánchez-Mateos P, Teixidó J: The chemokine receptor CXCR4 and the metalloproteinase MT1-MMP are mutually required during melanoma metastasis to lungs. Am J Pathol. 2009, 174: 602-612. 10.2353/ajpath.2009.080636.CrossRefPubMedPubMedCentral Bartolomé RA, Ferreiro S, Miquilena-Colina ME, Martínez-Prats L, Soto-Montenegro ML, García-Bernal D, Vaquero JJ, Agami R, Delgado R, Desco M, Sánchez-Mateos P, Teixidó J: The chemokine receptor CXCR4 and the metalloproteinase MT1-MMP are mutually required during melanoma metastasis to lungs. Am J Pathol. 2009, 174: 602-612. 10.2353/ajpath.2009.080636.CrossRefPubMedPubMedCentral
6.
go back to reference Deng H, Guo RF, Li WM, Zhao M, Lu YY: Matrix metalloproteinase 11 depletion inhibits cell proliferation in gastric cancer cells. Biochem Biophys Res Commun. 2005, 326: 274-281. 10.1016/j.bbrc.2004.11.027.CrossRefPubMed Deng H, Guo RF, Li WM, Zhao M, Lu YY: Matrix metalloproteinase 11 depletion inhibits cell proliferation in gastric cancer cells. Biochem Biophys Res Commun. 2005, 326: 274-281. 10.1016/j.bbrc.2004.11.027.CrossRefPubMed
7.
go back to reference Kren L, Goncharuk VN, Krenová Z, Stratil D, Hermanová M, Skricková J, Sheehan CE, Ross JS: Expression of matrix metalloproteinases 3, 10 and 11 (stromelysins 1, 2 and 3) and matrix metalloproteinase 7 (matrilysin) by cancer cells in non-small cell lung neoplasms: Clinicopathologic studies. Cesk Patol. 2006, 42: 16-19.PubMed Kren L, Goncharuk VN, Krenová Z, Stratil D, Hermanová M, Skricková J, Sheehan CE, Ross JS: Expression of matrix metalloproteinases 3, 10 and 11 (stromelysins 1, 2 and 3) and matrix metalloproteinase 7 (matrilysin) by cancer cells in non-small cell lung neoplasms: Clinicopathologic studies. Cesk Patol. 2006, 42: 16-19.PubMed
8.
go back to reference Thorns V, Walter GF, Thorns C: Expression of MMP-2, MMP-7, MMP-9, MMP-10 and MMP-11 in human astrocytic and oligodendroglial gliomas. Anticancer Res. 2003, 23: 3937-3944.PubMed Thorns V, Walter GF, Thorns C: Expression of MMP-2, MMP-7, MMP-9, MMP-10 and MMP-11 in human astrocytic and oligodendroglial gliomas. Anticancer Res. 2003, 23: 3937-3944.PubMed
9.
go back to reference Wasenius VM, Hemmer S, Kettunen E, Knuutila S, Franssila K, Joensuu H: Hepatocyte growth factor receptor, matrix metalloproteinase-11, tissue inhibitor of metalloproteinase-1, and fibronectin are up-regulated in papillary thyroid carcinoma: a cDNA and tissue microarray study. Clin Cancer Res. 2003, 9: 68-75.PubMed Wasenius VM, Hemmer S, Kettunen E, Knuutila S, Franssila K, Joensuu H: Hepatocyte growth factor receptor, matrix metalloproteinase-11, tissue inhibitor of metalloproteinase-1, and fibronectin are up-regulated in papillary thyroid carcinoma: a cDNA and tissue microarray study. Clin Cancer Res. 2003, 9: 68-75.PubMed
10.
go back to reference Mellick AS, Blackmore D, Weinstein SR, Griffiths LR: An assessment of MMP and TIMP gene expression in cell lines and stroma tumour differences in microdissected breast cancer biopsies. Tumour Biol. 2003, 24: 258-270. 10.1159/000076140.CrossRefPubMed Mellick AS, Blackmore D, Weinstein SR, Griffiths LR: An assessment of MMP and TIMP gene expression in cell lines and stroma tumour differences in microdissected breast cancer biopsies. Tumour Biol. 2003, 24: 258-270. 10.1159/000076140.CrossRefPubMed
11.
go back to reference Zhao ZS, Chu YQ, Ye ZY, Wang YY, Tao HQ: Overexpression of matrix metalloproteinase 11 in human gastric carcinoma and its clinicopathologic significance. Hum Pathol. 2010, 41: 686-696. 10.1016/j.humpath.2009.10.010.CrossRefPubMed Zhao ZS, Chu YQ, Ye ZY, Wang YY, Tao HQ: Overexpression of matrix metalloproteinase 11 in human gastric carcinoma and its clinicopathologic significance. Hum Pathol. 2010, 41: 686-696. 10.1016/j.humpath.2009.10.010.CrossRefPubMed
12.
go back to reference Min Y, Adachi Y, Yamamoto H, Imsumran A, Arimura Y, Endo T, Hinoda Y, Lee CT, Nadaf S, Carbone DP, Imai K: Insulin-like growth factor I receptor blockade enhances chemotherapy and radiation responses and inhibits tumour growth in human gastric cancer xenografts. Gut. 2005, 54: 591-600. 10.1136/gut.2004.048926.CrossRefPubMedPubMedCentral Min Y, Adachi Y, Yamamoto H, Imsumran A, Arimura Y, Endo T, Hinoda Y, Lee CT, Nadaf S, Carbone DP, Imai K: Insulin-like growth factor I receptor blockade enhances chemotherapy and radiation responses and inhibits tumour growth in human gastric cancer xenografts. Gut. 2005, 54: 591-600. 10.1136/gut.2004.048926.CrossRefPubMedPubMedCentral
13.
go back to reference Tsuchida Y, Therasse P: Response evaluation criteria in solid tumors (RECIST): new guidelines. Med Pediatr Oncol. 2001, 37: 1-3. 10.1002/mpo.1154.CrossRefPubMed Tsuchida Y, Therasse P: Response evaluation criteria in solid tumors (RECIST): new guidelines. Med Pediatr Oncol. 2001, 37: 1-3. 10.1002/mpo.1154.CrossRefPubMed
14.
go back to reference Li H, Diao YT, Ma JX, Xu AQ, Li HQ, Ma Q, Yin C, Cui J, Cui YC: Time trends on the prevalence of cancer during 1970-2005 in Shandong province. Zhonghua Liu Xing Bing Xue Za Zhi. 2009, 30: 592-595. [In Chinese]PubMed Li H, Diao YT, Ma JX, Xu AQ, Li HQ, Ma Q, Yin C, Cui J, Cui YC: Time trends on the prevalence of cancer during 1970-2005 in Shandong province. Zhonghua Liu Xing Bing Xue Za Zhi. 2009, 30: 592-595. [In Chinese]PubMed
15.
go back to reference Pei D: Matrix metalloproteinases target protease-activated receptors on the tumor cell surface. Cancer Cell. 2005, 7: 207-208. 10.1016/j.ccr.2005.02.011.CrossRefPubMed Pei D: Matrix metalloproteinases target protease-activated receptors on the tumor cell surface. Cancer Cell. 2005, 7: 207-208. 10.1016/j.ccr.2005.02.011.CrossRefPubMed
16.
go back to reference Mañes S, Mira E, Barbacid MM, Ciprés A, Fernández-Resa P, Buesa JM, Mérida I, Aracil M, Márquez G, Martínez-A C: Identification of insulin-like growth factor-binding protein-1 as a potential physiological substrate for human stromelysin-3. J Biol Chem. 1997, 272: 25706-25712. 10.1074/jbc.272.41.25706.CrossRefPubMed Mañes S, Mira E, Barbacid MM, Ciprés A, Fernández-Resa P, Buesa JM, Mérida I, Aracil M, Márquez G, Martínez-A C: Identification of insulin-like growth factor-binding protein-1 as a potential physiological substrate for human stromelysin-3. J Biol Chem. 1997, 272: 25706-25712. 10.1074/jbc.272.41.25706.CrossRefPubMed
17.
go back to reference Soni S, Mathur M, Shukla NK, Deo SV, Ralhan R: Stromelysin-3 expression is an early event in human oral tumorigenesis. Int J Cancer. 2003, 107: 309-316. 10.1002/ijc.11366.CrossRefPubMed Soni S, Mathur M, Shukla NK, Deo SV, Ralhan R: Stromelysin-3 expression is an early event in human oral tumorigenesis. Int J Cancer. 2003, 107: 309-316. 10.1002/ijc.11366.CrossRefPubMed
18.
go back to reference Arora S, Kaur J, Sharma C, Mathur M, Bahadur S, Shukla NK, Deo SV, Ralhan R: Stromelysin 3, Ets-1, and vascular endothelial growth factor expression in oral precancerous and cancerous lesions: correlation with microvessel density, progression, and prognosis. Clin Cancer Res. 2005, 11: 2272-2284. 10.1158/1078-0432.CCR-04-0572.CrossRefPubMed Arora S, Kaur J, Sharma C, Mathur M, Bahadur S, Shukla NK, Deo SV, Ralhan R: Stromelysin 3, Ets-1, and vascular endothelial growth factor expression in oral precancerous and cancerous lesions: correlation with microvessel density, progression, and prognosis. Clin Cancer Res. 2005, 11: 2272-2284. 10.1158/1078-0432.CCR-04-0572.CrossRefPubMed
19.
go back to reference Denys H, De Wever O, Nusgens B, Kong Y, Sciot R, Le AT, Van Dam K, Jadidizadeh A, Tejpar S, Mareel M, Alman B, Cassiman JJ: Invasion and MMP expression profile in desmoid tumours. Br J Cancer. 2004, 90: 1443-1449. 10.1038/sj.bjc.6601661.CrossRefPubMedPubMedCentral Denys H, De Wever O, Nusgens B, Kong Y, Sciot R, Le AT, Van Dam K, Jadidizadeh A, Tejpar S, Mareel M, Alman B, Cassiman JJ: Invasion and MMP expression profile in desmoid tumours. Br J Cancer. 2004, 90: 1443-1449. 10.1038/sj.bjc.6601661.CrossRefPubMedPubMedCentral
20.
go back to reference Kettunen E, Anttila S, Seppänen JK, Karjalainen A, Edgren H, Lindström I, Salovaara R, Nissén AM, Salo J, Mattson K, Hollmén J, Knuutila S, Wikman H: Differentially expressed genes in nonsmall cell lung cancer: expression profiling of cancer-related genes in squamous cell lung cancer. Cancer Genet Cytogenet. 2004, 149: 98-106. 10.1016/S0165-4608(03)00300-5.CrossRefPubMed Kettunen E, Anttila S, Seppänen JK, Karjalainen A, Edgren H, Lindström I, Salovaara R, Nissén AM, Salo J, Mattson K, Hollmén J, Knuutila S, Wikman H: Differentially expressed genes in nonsmall cell lung cancer: expression profiling of cancer-related genes in squamous cell lung cancer. Cancer Genet Cytogenet. 2004, 149: 98-106. 10.1016/S0165-4608(03)00300-5.CrossRefPubMed
21.
go back to reference Hourihan RN, O'Sullivan GC, Morgan JG: Transcriptional gene expression profiles of oesophageal adenocarcinoma and normal oesophageal tissues. Anticancer Res. 2003, 23: 161-165.PubMed Hourihan RN, O'Sullivan GC, Morgan JG: Transcriptional gene expression profiles of oesophageal adenocarcinoma and normal oesophageal tissues. Anticancer Res. 2003, 23: 161-165.PubMed
22.
go back to reference Boulay A, Masson R, Chenard MP, El Fahime M, Cassard L, Bellocq JP, Sautès-Fridman C, Basset P, Rio MC: High cancer cell death in syngeneic tumors developed in host mice deficient for the stromelysin-3 matrix metalloproteinase. Cancer Res. 2001, 61: 2189-2193.PubMed Boulay A, Masson R, Chenard MP, El Fahime M, Cassard L, Bellocq JP, Sautès-Fridman C, Basset P, Rio MC: High cancer cell death in syngeneic tumors developed in host mice deficient for the stromelysin-3 matrix metalloproteinase. Cancer Res. 2001, 61: 2189-2193.PubMed
23.
go back to reference Andarawewa KL, Boulay A, Masson R, Mathelin C, Stoll I, Tomasetto C, Chenard MP, Gintz M, Bellocq JP, Rio MCL: Dual stromelysin-3 function during natural mouse mammary tumor virus-ras tumor progression. Cancer Res. 2003, 63: 5844-5849.PubMed Andarawewa KL, Boulay A, Masson R, Mathelin C, Stoll I, Tomasetto C, Chenard MP, Gintz M, Bellocq JP, Rio MCL: Dual stromelysin-3 function during natural mouse mammary tumor virus-ras tumor progression. Cancer Res. 2003, 63: 5844-5849.PubMed
24.
go back to reference Têtu B, Trudel D, Wang CS: Proteases by reactive stromal cells in cancer: an attractive therapeutic target. Bull Cancer. 2006, 93: 944-948. [In French]PubMed Têtu B, Trudel D, Wang CS: Proteases by reactive stromal cells in cancer: an attractive therapeutic target. Bull Cancer. 2006, 93: 944-948. [In French]PubMed
25.
go back to reference Cheng CW, Yu JC, Wang HW, Huang CS, Shieh JC, Fu YP, Chang CW, Wu PE, Shen CY: The clinical implications of MMP-11 and CK-20 expression in human breast cancer. Clin Chim Acta. 2010, 411: 234-241. 10.1016/j.cca.2009.11.009.CrossRefPubMed Cheng CW, Yu JC, Wang HW, Huang CS, Shieh JC, Fu YP, Chang CW, Wu PE, Shen CY: The clinical implications of MMP-11 and CK-20 expression in human breast cancer. Clin Chim Acta. 2010, 411: 234-241. 10.1016/j.cca.2009.11.009.CrossRefPubMed
26.
go back to reference Kren L, Goncharuk VN, Krenová Z, Stratil D, Hermanová M, Skricková J, Sheehan CE, Ross JS: Expression of matrix metalloproteinases 3, 10 and 11 (stromelysins 1, 2 and 3) and matrix metalloproteinase 7 (matrilysin) by cancer cells in non-small cell lung neoplasms: Clinicopathologic studies. Cesk Patol. 2006, 42: 16-19.PubMed Kren L, Goncharuk VN, Krenová Z, Stratil D, Hermanová M, Skricková J, Sheehan CE, Ross JS: Expression of matrix metalloproteinases 3, 10 and 11 (stromelysins 1, 2 and 3) and matrix metalloproteinase 7 (matrilysin) by cancer cells in non-small cell lung neoplasms: Clinicopathologic studies. Cesk Patol. 2006, 42: 16-19.PubMed
27.
go back to reference Ajani JA, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Awad L, Van Cutsem E: Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group. J Clin Oncol. 2007, 25: 3210-3216. 10.1200/JCO.2006.08.3956.CrossRefPubMed Ajani JA, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Awad L, Van Cutsem E: Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group. J Clin Oncol. 2007, 25: 3210-3216. 10.1200/JCO.2006.08.3956.CrossRefPubMed
Metadata
Title
Serum levels of MMP-11 correlate with clinical outcome in Chinese patients with advanced gastric adenocarcinoma
Authors
Dong Yan
Hong Dai
Jin-Wei Liu
Publication date
01-12-2011
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2011
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-11-151

Other articles of this Issue 1/2011

BMC Cancer 1/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine